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Soft tissue sarcomas (STS) are rare malignant tumours derived from connective tissue. They constitute about 1% of 
malignancies occurring in adults. We distinguish over 60 subtypes of soft tissue sarcoma, each with a unique clinical 
course and a diversified response to systemic treatment. The prognosis for patients with locally advanced, unresectable 
or metastatic disease remains poor. For years, doxorubicin — used alone or in combination with ifosfamide — has 
been the basis of treatment for these patients. Trabectedin is a relatively new molecule registered in the treatment 
of patients diagnosed with STS. The drug was originally obtained from marine tunicates (Ecteinascidia turbinata), 
currently it is obtained semi-synthetically. So far, a number of potential mechanisms of trabectedin have been descri-
bed, including DNA-binding, disruption of DNA repair mechanisms and cell cycle, as well as effects on transcription 
factors and the tumour microenvironment. The aim of the following review is to summarize the current knowledge 
on the efficacy and safety of trabectedin in the treatment of patients diagnosed with STS.
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Introduction
STS is a group of rare malignant neoplasms of mesen-
chymal origin. The standard treatment for locally advanced 
disease is radical resection of the tumour usually with pre- 
or post-operative radiotherapy. The place of perioperative 
chemotherapy is still not fully established. However, about 
50% of patients diagnosed with high-grade tumours will 
develop metastatic disease. The prognosis remains bad, 
and the median overall survival (OS) is about 12 months. 
The basis of treatment in the case of diagnosis of metastatic 
disease is a systemic treatment. Unfortunately, the number 
of drugs with proven activity in this indication is still low. For 
many years, the most important drugs used in palliative tre-
atment of STS have been doxorubicin and ifosfamide. There 
is also a number of new particles with proven efficacy, such 
as olaratumab, pazopanib, eribulin or trabecetidin, used for 
the longest time among this group [1].
Trabectedin is a synthetic alkylating agent, originally 
isolated from Caribbean tunicates Ecteinascidia turbinata 
[2]. The success of trabectedin in initial clinical trials among 
patients diagnosed with MTM has resulted in drug appro-
val in many countries. Two years ago the results of a large, 
randomized phase III trial being the final trial approving the 
drug in the United States [3] were published. With limited 
systemic therapy options available to treat patients with 
STS, trabectedin is an important treatment line in this rare 
diagnosis.
Trabectedin — mechanism of action 
A number of potential mechanisms of antitumor activity 
of trabectedin have been described, including cytotoxic and 
antiproliferative effects, inhibition of gene transcription and 
indirect immunological and anti-angiogenic effects. Howe-
ver, the effects of the drug are still not fully understood [4].
Molecular evidence suggests that the cytotoxic effect of 
trabectedin is due to its DNA-binding. In fact, trabectedin 
binds to a minor DNA groove, causing DNA double helix 
to be distorted with an interruption in the DNA itself. The 
interaction between trabectedin and the minor DNA groove 
determines structural changes in the molecule, resulting in 
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a cascade of events that affects a number of transcription 
factors, DNA-binding proteins and DNA repair pathways, 
resulting in G2-M cell cycle arrest and eventually apoptosis 
[2]. It has been observed that cytotoxic mechanisms of 
trabectedin are affected by DNA repair mechanisms, such 
as nucleotide excision repair (NER) and homologous re-
combination repair (HRR), which recognize DNA damage 
and recruit various factors to repair the damaged place. Cell 
repair machinery, including both NER and HRR systems, is 
crucial for the interaction between trabectedin and DNA 
and appears to be the most important determinant of drug 
susceptibility [5]. Also the direct interaction between tra-
bectedin and RNA polymerase II (pol II) has been described, 
causing the transcription process to stop, pol II degradation 
through the proteasome pathway and premature termina-
tion of the RNA transcript [2]. This type of antiproliferative 
mechanism appears to be particularly effective in MLPS 
(myxoid liposarcoma), which is the STS subtype most sen-
sitive to trabectedin therapy. Furthermore, trabectedin has 
a stimulating effect on the differentiation of MLPS tumor 
cells. The tumor response to trabectedin in MLPS in vivo is 
characterized by tumor cell death and induction of mature 
adipocytes [6].
In addition to this cytotoxic activity, trabectedin mo-
dulates tumour microenvironment and it seems that this is 
the most important part of its therapeutic effect. The drug 
exerts a selected cytotoxic effect against tumour-associa-
ted monocytes and macrophages (TAM) present in tumour 
tissues. They are key promoters of inflammation associated 
with cancer. TAMs have a pro-cancer activity, including the 
production of growth factors that are necessary for pro-
liferation, neoangiogenesis and the action of proteolytic 
enzymes. These elements degrade the extracellular matrix, 
determining the invasion of cancer cells and facilitating 
escape from the immune system [7]. It has been shown 
that trabectedin significantly reduces the expression of cy-
tokines, chemokine, mediators of inflammation and angio-
genesis, for example, interleukin-6, or vascular endothelial 
growth factor modifying the tumour microenvironment, 
thereby contributing to anti-angiogenic and antitumor ef-
fect of the drug [8].
The efficacy of trabectedin in clinical trials
Phase II clinical trials
The year 2004 saw the publication of the results of two 
phase II clinical trials that demonstrated the efficacy of trabec-
tedin in the treatment of MTM. The first of these studies was 
conducted on a group of 54 previously treated patients. There 
was a low rate of objective response to treatment — 4%, but 
a high rate of disease control after six months of therapy — 
24%. Trabectedin was administered at a dose of 1.5 mg/m2, 
for 24 hours every three weeks [9]. The second study noted 
again a low response rate of 8% and one year OS amounting 
to 53% in 36 previously treated patients with STS. The same 
dosing regimen of trabectedin was also used in this study (1.5 
mg/m2, over 24 hours every three weeks) [10].
Promising results of the Phase II studies led EORTC (Eu-
ropean Organization for the Research and Treatment of 
Cancer) to conduct a phase II trabectedin trial in 104 patients 
in the second and third line of treatment. Again, a low rate 
of objective responses of 8% was noted. The six-month PFS 
was 29% and the median overall survival was 9.2 months 
[11]. A further phase II trial was carried out in 36 patients 
to evaluate the activity of trabectedin in the first line of 
treatment. The treatment response rate was 17%, and the 
annual PFS and OS rates were 21% and 72% respectively [12].
Then a phase II randomized study was conducted, inc-
luding 270 patients diagnosed with leiomyosarcomas (LMS) 
and liposarcoma (LPS). Patients were randomized to one 
of two arms — in the first the drug was given at a dose of 
1.5 mg/m2 for 24 hours every three weeks, in the other arm at 
a dose of 0.58 mg/m2 for 3 hours once a week for three weeks 
out of four. Prior to enrolment, patients had to document 
the disease progression while receiving doxorubicin and 
ifosfamide. The 24-hour infusion regimen showed a much 
longer mean time to progression (TTP) (3.7 vs 2.3 months) 
and progression-free survival (PFS) 3.3 vs 2.3 months compa-
red to the 3-hour infusion schedule. There was no significant 
difference in the overall survival between the two arms of 
the study, but there was a strong trend favouring the 24-
hour infusion schedule (13.9 months vs 11.8 months) [13]. 
The results of this study led to the registration of trabectedin 
in the European Union in 2007.
Trabectedin is an expensive drug and has some side 
effects, which is why it was very important to ask whether 
the treatment should be continued until it is effective or it 
is possible to stop it after achieving control of the disease. 
The second phase II trial involved 53 patients with at least 
stabilization after 6 cycles of trabectedin. They were divided 
into one of the two arms of the study at random. In the first 
arm the treatment was continued until the disease progres-
sed, in the second one it was discontinued. The percentage 
of PFS at 6 months after randomization was 51.9% in the 
group where trabectedin was not discontinued compared 
to 23.1% in the group where trabectedin was discontinued 
after 6 cycles. Toxicity did not increase significantly with 
continuation of therapy. This study confirms that treatment 
with trabectedin should not be discontinued after the dise-
ase has been controlled and therapy should be continued 
as maintenance treatment [14].
Phase III clinical trials
Trabectedin has a higher efficacy in the treatment of 
patients diagnosed with so-called sarcomas associated with 
translocation (such as, for example, MLPS or synovial sarco-
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ma). Therefore, this group of patients was selected for the 
study in which the drug was compared with doxorubicin, 
which is the current standard of first-line treatment. In the 
phase III study, 121 patients with translocation sarcomas 
were randomly assigned to the arm in which they received 
trabectedin or doxorubicin in the first line of treatment. 
There was no significant difference in PFS between the 
two arms, which was the primary endpoint of the study. At 
the time of analysis, 63.9% and 58.3% of patients were still 
alive in the arms with trabectedin and doxorubicin (without 
a statistically significant difference in overall survival) re-
spectively. The objective response rate according to RECIST 
criteria was significantly higher in the doxorubicin group 
(27%) compared to trabectedin (5.9%). However, when the 
response was assessed according to Choi’s criteria, differen-
ces between doxorubicin (45.9%) and trabectedin (37.3%) 
were smaller [15]. Thus, doxorubicin (or doxorubicin based 
regimens) remains the standard first line treatment.
The pivotal phase III trial compared the use of trabecte-
din to dacarbazine in patients with locally advanced/meta-
static LMS and LPS. Patients were randomized in a 2:1 ratio 
to the arm with trabectedin or dacarbazine. A total of 518 
patients took part in the study, 345 of whom were ran-
domly assigned to the trabectedin arm and 173 patients 
to the dacarbazine arm. In the final PFS analysis, the use of 
trabectedin was associated with a reduction in the risk of 
disease progression or death compared to dacarbazine by 
45% (the median PFS for trabectedin was 4.2 vs 1.5 mon-
ths for dacarbazine, hazard ratio 0.55; p < 0.001). Benefits 
were observed in all pre-planned subgroup analyses. An 
interim OS analysis (64% censored) showed a 13% reduc-
tion in the risk of death in the trabectedin arm compared 
with dacarbazine (median OS for trabectedin was 12.4 to 
12.9 months for dacarbazine, hazard ratio, 0.87; p = 0, 37). 
Based on a significant improvement in PFS for the arm with 
trabectedin, this drug was registered in the United States in 
October 2015 for the treatment of patients diagnosed with 
advanced LPS and LMS [3, 16].
At this year’s ASCO 2018 meeting (American Society of 
Clinical Oncology) the results of the next phase III trial were 
presented. The study compared the efficacy and safety of 
trabectedin to the best supportive care (BSC) in patients dia-
gnosed with STS after failure of at least one line of systemic 
treatment (no more than previous 3 lines of chemotherapy). 
In the case of confirmation of further disease progression, 
patients in the BSC arm were able to go to the arm with 
trabectedin (cross-over option).
The primary endpoint of the study was PFS. The study 
included both patients with so-called L-sarcomas (LPS and 
LMS) as well as other MTM subtypes. In the group receiving 
trabectedin, the objective response rate (ORR) was 11.8%, 
all responses were observed in the L-sarcoma group (ORR 
in this group 18.8%). 23% of patients in the trabectedin arm 
received more than 9 courses of treatment. The median 
PFS was 1.5 months in the BSC arm and 3.1 months in the 
trabectedin arm (HR: 0.39, p < 0.0001). In the L-sarcoma 
cohort, the median PFS was 1.4 months in the BSC arm and 
5.1 months in the drug arm (HR: 0.29, p < 0.0001), while 
in the group without L-sarcomas it was 1.5 m and 1.8 m 
respectively (p = 0.16). Cross-over was performed in 92% 
of patients included in the BSC arm. After a median follow-
-up of 25.7 months, the differences between the two arms 
in terms of OS were not statistically significant and were 
13.6 months for the drug arm vs 10.8 months for the BSC 
arm (p = 0.86) [17]. Again, these results confirm the higher 
efficacy of the drug in patients with the diagnosis of the so-
-called L-sarcomas when compared to other MTM subtypes.
Also in the published results of the extended drug access 
program, which included 1895 patients diagnosed with STS 
treated with trabectedin, the results achieved in the group of 
patients diagnosed with L-sarcomas are significantly better. 
ORR in the group of L-sarcomas was 6.9% compared to 4% 
in the group of other histological subtypes. OS was also si-
gnificantly better in the group of L-sarcomas and amounted 
to 16.2 vs 8.4 months [18]. 
In Poland, the drug is available as part of the National 
Health Fund drug program only for patients diagnosed with 
L-sarcomas. In 2015, we published the results of trabectedin 
treatment of 50 patients with LPS and LMS at the Maria Skło-
dowska-Curie Memorial Cancer Center and Institute of Onco-
logy in Warsaw. The median number of given treatment cycles 
was 5 (range 2–40); 18 patients (36%) received ≥ 10 cycles. 
Four patients (8%) had a partial response, in 23 (46%) a disease 
stabilization was noted (for a minimum of 3 months), and in 23 
(46%) — disease progression. After six months of treatment, 
47% of patients were progression-free, more in the group with 
LPS — 66% compared with 27% in the LMS group (p = 0.023). 
PFS was significantly longer in patients receiving trabectedin in 
the 2nd or 3rd line of treatment (median 7 months) than > 3rd line 
of treatment (median 2 months) p = 0.038. The median overall 
survival (OS) was 13 months [19]. Table I summarizes the results 
of clinical trials on efficacy of trabactedin in STS.
Trabectedin in the treatment of myxoid 
liposarcomas (MLPS)
It has been found that trabectedin is particularly effecti-
ve in sarcomas associated with translocation, such as MLPS, 
exerting anti-tumour activity, inter alia, by inactivation of an 
oncogene FUS-CHOP, which is believed to alter expression 
of a protein encoding gene and induce adipocyte differen-
tiation [6].
Results of two retrospective studies were published on 
the efficacy of trabectedin only among patients with this 
diagnosis. In the first one including a group of 32 patients 
the drug was used after failure of previous therapies. The 
objective response rate was 50%, 2 patients had a complete 
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remission (CR), 14 had partial response (PR) to treatment. 
The stabilization of the disease (SD) was noted in another 
14 patients. 90% of patients achieved disease control (CR 
+ PR + SD). The median PFS for the whole group was 17 mon-
ths. Six months after the start of treatment, 90% of subjects 
were free of disease progression. Some patients after the 
use of this treatment were qualified for resection of residual 
lesions, which was not possible before starting the therapy. 
The median duration of treatment was 10 months and 24 
subjects (75%) received more than 8 courses of treatment 
[20]. In another study conducted in a group of 51 patients 
from several centres, the results were quite similar: 2 CR, 
24 PR were found, in total 51% of patients had an objective 
response to treatment. The median PFS was 14 months 
and the proportion of patients free of progression after six 
months after starting treatment — 88%. Interestingly, 17 of 
23 responders were found to have changes in the density 
of neoplastic lesions assessed in the CT scan or reduced 
contrast uptake in the magnetic resonance imaging study, 
which preceded the finding of tumour size reduction [21].
Particularly good results among patients with the dia-
gnosis of metastatic MLPS encouraged the assessment of 
the usefulness of the drug used as pre-operative therapy. In 
a study conducted by the Italian sarcoma group, 23 patients 
received the drug pre-operatively for 3–6 cycles of treat-
ment. Then, the response to treatment was evaluated — in 3 
patients CR was noted, confirmed in later histopathological 
examination, in 12 patients showed a significant response 
to the treatment which also manifested in the histopatho-
logical material as decreased tumour cellularity, decreased 
number of blood vessels, as well as greater maturity of 
tumour-forming lipoblasts. In 7 people, PR was diagnosed. 
None of the patients had progression of disease [22].
Side effects
Phase II and III trials showed that trabectedin is a fairly 
well-tolerated treatment, with no cumulative toxicity. The 
most common side effects of the drug are nausea, tiredness, 
vomiting, constipation and oedema. Adverse drug reactions 
of grade III and IV occur only in about 10% of treated cases. 
Table I. The results of clinical trials on the efficacy of trabectedin in STS
Trial Number of patients 
treated with 
trabectedin
Treatment 
line
Histological subtypes Results
Yovine et al. [9]
II Phase
54 ≥ 2 LMS 22 (41%)
LPS 6 (11%)
GIST 4 (7%)
Synovial sarcoma 3 (6%)
MFH 3 (6%)
Fibrosarcoma 4 (7%)
Other 12 (22%)
PR 2 (3.7%)
SD ≥ 6 months 9 
(16.7%) 
SD ≥ 2 ≤ 6 months 9 
(16.7%)
PD 28 (51.9%)
6-months PFS 24.1% 
Median OS 12.8 
months
Le Cesne et al. [11]
II Phase
99 ≥ 2 LMS 43 (41%)
LPS 10 (9.6%)
Sarcoma synoviale 18 (17.3%)
MFH 6 (5.7%)
Fibrosarcoma 1
Other 26
PR 8 (8.1%)
SD 45 (45.5%)
PD 35 (35.4%)
6-months PFS 29%
Median OS 9.2 
months
Garcia-Carbonero 
et al. [10]
II Phase
36 ≥ 2 LMS 13 (36%)
LPS 10 (28%)
MPNST 2 (6%)
Synovial sarcoma 6 (17%)
Other 5 (13%)
CR 1 (3%)
PR 2(6%)
Median OS 12.1 
months
OS after 1 year 53.1%
Median PFS 1.7 
months
Blay et al. [15] 
(vs Doxorubicin)
III Phase
60 1 MLPS 23 (37.7%)
Other translocation related 
subtypes 28 (45.9%)
Other STS subtypes 10 (16.4%)
PR 3 (5.9%)
SD 39 (76.5%)
PD 6 (11.8 %)
No statistically 
significant difference 
between the study 
arms in PFS and OS
Demetri et al.
(Dacarbazine) [3]
III Phase
345 ≥ 2 LMS 252 (73%)
LPS 93 (27%)
ORR 34 (9.9%)
SD 177 (51%)
Median PFS 4.2 
months 
(vs 1.5 months for 
dacarbazine  
p < 0.001)
Le Cesne et al. [17]
(vs best supportive 
care — BSC)
III Phase
52 ≥ 2 LMS 31.1% 
LPS 29.1% 
Pleomorphic sarcoma 10.7% 
Myxofibrosarcoma 7.8%
Synovial sarcoma 4.9%
Other 16.5% 
PR 7 (13.7%)
SD 34 (66.7%)
PD 10 (19.6 %)
Median PFS 3.12 
months (vs 1.5 
months for BSC  
p < 0.0001)
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The most common grade III and IV adverse reactions are: 
reversible elevation of aminotransferases and myelotoxicity, 
in particular neutropenia and anaemia [4, 23].
Transient increase of transaminases typically occurs 
several days after administration of trabectedin and it 
usually resolves spontaneously after about 15 days. If the 
level of transaminase does not normalize after 21 days, it 
is necessary to postpone treatment or reduce the dose. 
Intravenous premedication with corticosteroids, such as 
dexamethasone, is strongly recommended as an antiemetic 
and prophylactic for hepatic toxicity. Some clinical trials 
have shown that concomitant steroid treatment induces 
hepatic activity of the cytochrome P450 variant 3A4, redu-
cing exposure to trabectedin in the liver and consequently 
correlated hepatotoxicity [24].
Rarely occurring, potentially dangerous side effects of 
trabectedin include neutropenic fever, rhabdomyolysis, car-
diotoxicity or extravasation of the drug (the drug must be 
administered through a catheter inserted into the central 
vein due to the strong local irritant action of the drug on 
the vessel wall) [25].
Summary
Patients diagnosed with unresectable/metastatic soft 
tissue sarcoma are still a group of patients with poor pro-
gnosis. There are still not many systemic treatment options 
available. Research in recent years has, however, resulted 
in a number of new drug registrations in this indication. 
One of them is trabectedin — a drug with proven efficacy, 
especially in patients diagnosed with so-called L-sarcomas. 
The unique anti-tumour activity of trabectedin is not only 
its cytotoxic activity, but also its ability to modulate the 
tumour microenvironment. Trabectedin in subsequent stu-
dies shows a constant activity in patients after failure of 
treatment with doxorubicin, allowing to obtain long-term 
control of the disease.
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